JP2022176933A5 - - Google Patents

Download PDF

Info

Publication number
JP2022176933A5
JP2022176933A5 JP2022119504A JP2022119504A JP2022176933A5 JP 2022176933 A5 JP2022176933 A5 JP 2022176933A5 JP 2022119504 A JP2022119504 A JP 2022119504A JP 2022119504 A JP2022119504 A JP 2022119504A JP 2022176933 A5 JP2022176933 A5 JP 2022176933A5
Authority
JP
Japan
Prior art keywords
protein
toxin
binder
fusion protein
protoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022119504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022176933A (ja
JP7728587B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2020/054263 external-priority patent/WO2020169620A1/en
Application filed filed Critical
Publication of JP2022176933A publication Critical patent/JP2022176933A/ja
Publication of JP2022176933A5 publication Critical patent/JP2022176933A5/ja
Application granted granted Critical
Publication of JP7728587B2 publication Critical patent/JP7728587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022119504A 2019-02-18 2022-07-27 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法 Active JP7728587B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19157839.2 2019-02-18
EP19157839 2019-02-18
PCT/EP2020/054263 WO2020169620A1 (en) 2019-02-18 2020-02-18 Method of producing a binder-toxin fusion protein in a plant cell or a whole plant
JP2021548219A JP7150999B2 (ja) 2019-02-18 2020-02-18 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021548219A Division JP7150999B2 (ja) 2019-02-18 2020-02-18 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Publications (3)

Publication Number Publication Date
JP2022176933A JP2022176933A (ja) 2022-11-30
JP2022176933A5 true JP2022176933A5 (cg-RX-API-DMAC7.html) 2023-02-09
JP7728587B2 JP7728587B2 (ja) 2025-08-25

Family

ID=65717705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021548219A Active JP7150999B2 (ja) 2019-02-18 2020-02-18 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法
JP2022119504A Active JP7728587B2 (ja) 2019-02-18 2022-07-27 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021548219A Active JP7150999B2 (ja) 2019-02-18 2020-02-18 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Country Status (11)

Country Link
US (1) US20220090113A1 (cg-RX-API-DMAC7.html)
EP (2) EP3927831B1 (cg-RX-API-DMAC7.html)
JP (2) JP7150999B2 (cg-RX-API-DMAC7.html)
KR (1) KR102398485B1 (cg-RX-API-DMAC7.html)
CN (2) CN115925972A (cg-RX-API-DMAC7.html)
BR (1) BR112021016348A2 (cg-RX-API-DMAC7.html)
CA (1) CA3128793C (cg-RX-API-DMAC7.html)
ES (1) ES3055338T3 (cg-RX-API-DMAC7.html)
IL (1) IL285719B (cg-RX-API-DMAC7.html)
WO (1) WO2020169620A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105654B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102398485B1 (ko) * 2019-02-18 2022-05-16 에이티비 테라퓨틱스 식물 세포 또는 식물 전체에서 결합제-독소 융합 단백질의 생산 방법
US20230203108A1 (en) * 2020-05-28 2023-06-29 Chugai Seiyaku Kabushiki Kaisha Improved granzyme b variant
WO2022038152A1 (en) 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
EP4328243A4 (en) * 2021-04-20 2025-05-21 Korea University Research and Business Foundation Asymmetric antibody with improved cytotoxicity against cancer cell
CN117440971A (zh) * 2021-04-20 2024-01-23 高丽大学校产学协力团 具有提高的癌细胞杀灭功效的非对称抗体
WO2023156634A1 (en) 2022-02-17 2023-08-24 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
CN114605556B (zh) * 2022-03-10 2023-04-14 南开大学 一种增强植物根系募集功能细菌的融合蛋白及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6140075A (en) 1994-07-25 2000-10-31 Monsanto Company Method for producing antibodies and protein toxins in plant cells
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
CA2454048C (en) * 2001-07-17 2011-05-03 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
US20090148904A1 (en) * 2007-11-13 2009-06-11 Mayfield Stephen P Production of cytotoxic antibody-toxin fusion in eukaryotic algae
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US9586996B2 (en) 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
PH12012502433A1 (en) 2010-06-09 2013-02-11 Du Pont Regulatory sequences for modulating transgene expression in plants
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
WO2016187585A1 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Deimmunized linker and methods of use
CN105753986B (zh) * 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途
KR102398485B1 (ko) * 2019-02-18 2022-05-16 에이티비 테라퓨틱스 식물 세포 또는 식물 전체에서 결합제-독소 융합 단백질의 생산 방법

Similar Documents

Publication Publication Date Title
US20220267400A1 (en) Il-2 cytokine prodrugs comprising a cleavable linker
CN1241945C (zh) 用于抑制肥大细胞脱粒的杂合蛋白质及其用途
TWI710570B (zh) 用於治療代謝異常之組成物及方法
US20040081647A1 (en) Adzymes and uses thereof
CN108350039A (zh) 用于治疗疼痛的组合物和方法
JP2019513014A5 (cg-RX-API-DMAC7.html)
JP2021512122A5 (cg-RX-API-DMAC7.html)
EP1730198A2 (en) Adzymes and uses thereof
WO2017025698A1 (en) Bispecific, cleavable antibodies
JP2019069994A (ja) 標的化剤としてのGlaドメイン
JP2008503217A5 (cg-RX-API-DMAC7.html)
JP2023511074A (ja) 切断可能リンカーを含むサイトカインプロドラッグ
US20090169553A1 (en) Novel Protein Fusion/Tag Technology
EP0925363A1 (en) Self-secreting proteases
JP7402864B2 (ja) ポリユビキチンリンカーに結合された線形多機能性マルチマー生体分子及びその用途
JP2003522117A (ja) 治療薬の送達のための二機能性分子
JP2017501715A (ja) 慢性疼痛のためのマルチプロテアーゼ(multiprotease)治療薬
JP2003511007A5 (cg-RX-API-DMAC7.html)
CA2392202A1 (en) Constructs for delivery of therapeutic agents to neuronal cells
JP2003511078A (ja) 複数のエピトープと融合した組換えタンパク質の精製
US20240228585A1 (en) Fc-fusion protein therapeutic for the treatment of pancreatitis
JP2769083B2 (ja) エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP2024542978A5 (cg-RX-API-DMAC7.html)
WO2005061531A1 (en) A superantigen fusion protein used for antitumor therapy and the preparation thereof
JP5156953B2 (ja) 核酸切断剤